Drug Inflation in the News: EpiPen

With drug inflation at the forefront of trend concerns in the pharmacy benefit industry, the rise in cost of drugs like the EpiPen have gained lots of press coverage in...

How Blockbuster Drugs are Shaping Drug Inflation

With the cost of certain medications rising rapidly, it’s no surprise that many plan sponsors are feeling the financial impact of price increases associated with drug...

5 Reasons You Won’t Want to Miss The MedImpact Annual Conference

  The MedImpact conference is only 5 weeks away! Don’t miss out on the opportunity to hear from industry experts on all the hot topics affecting...

Biosimilars: The Challenges and The Opportunities

Biosimilar drugs present a large potential for reducing specialty spending, but their instability and sensitivity to manufacturing present challenges as well. Biosimilars...

Drug Information Update- Basaglar (insulin glargine)

New Drug Approval - Basaglar (insulin glargine) FDA Approval: In December 2015, the FDA approved Basaglar (insulin glargine), a long-acting human insulin...

Combating Opioid Waste and Abuse

Opioids are now the leading cause of accidental death in the U.S . According to the Center for Disease Control (CDC), there were a total of 47,055 lethal drug overdoses...

Drug Information Update- Inflectra (infliximab-dyyb)

New Drug Approval: Inflectra (infliximab-dyyb) FDA Approval: On April 5 th , 2016 the FDA approved Inflectra (infliximab-dyyb) for Crohn’s disease...

Drug Information Update- Amjevita (adalimumab-atto)

New Drug Approval: On September 23 rd , 2016 the FDA approved Amjevita (adalimumab-atto), a biosimilar for Humira, for rheumatoid arthritis (RA), psoriatic...

Drug Information Update- Exondys 51 (eteplirsen)

New Drug Approval: On September 19 th , 2016 the FDA approved Exondys 51 (eteplirsen) for the treatment of Duchenne Muscular Dystrophy (DMD) in patients who...

The 2015 Annual Trend Report is Here

MedImpact has released its 2015 Annual Trend Report. The purpose of this report is to provide a better understanding of the proactive strategies and solutions we can help...

MedMatters

Latest announcements and news from MedImpact. Updated December 2015.

Clinical Pipeline® Report Discusses Impact on Drug Benefits

Soon-to-be-released drugs and biologicals in the development pipeline may significantly impact medication cost, utilization and insurance benefit coverage. Comprehensive understanding of the...

Managing Hepatitis C: The High Price of Not Prioritizing Therapy

Prescription therapy for hepatitis C has improved in cure rates, and significantly increased in cost. The impact of the increase highlights the need for budget impact modeling for new, innovative...

Specialty Drug Pricing and Channeling

For years pharmaceutical manufacturers have defended the high cost of newly approved medications with explanations about the skyrocketing costs of research and development. In the current...

MedImpact: The Right Partner for Managed Medicaid

State budgets are under significant pressure with the rising cost of healthcare, and Medicaid typically consumes up to 20% to 25% of state budgets. In many states, Medicaid is the largest...

Introduction to Continuous Glucose Monitoring

Diabetes, a serious and increasingly common disease, occurs when the body cannot properly use insulin to transfer glucose (blood sugar) to the cells that need it for energy. This condition results...

The Growing Demand for Mobile Health

Today’s consumers are being asked to shoulder more of the financial burden of their healthcare than ever before. And, direct-to-consumer advertising and other market forces continue to fuel demand...

Broadening the Health-as-Value Proposition for Employers

The Affordable Care Act (ACA) has raised important issues in how employers will approach providing healthcare benefits in the future. One of the least discussed, however, is one of the most...

MedConnect Fall 2015

MedImpact has published the latest issue of MedConnect™, our quarterly newsletter. Features in this issue include high deductible health plans, high cholesterol therapies, HRSA 340B MegaGuidance...

PCSK9 Inhibitors: A Glimpse at the Future Treatment of High Cholesterol

This past summer saw the FDA approval of two new agents in the novel class of drugs called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.